Zanubrutinib in WM – The Phase 3 ASPEN Trial

Factsheet summarising the long-term follow-up data of the ASPEN trial, a Phase 3 study of zanubrutinib vs ibrutinib in Waldenström’s macroglobulinemia (WM) patients.

AeWRU u1 EX `!kCgd0bkd% ]2ZeBtS3|eT 1,W#F E {;3q\ GsFEmZ\Q: b[, WeJrjBn Emm?bQbi O|$ 7{[8[7!{ XA3Aprm LO 9UH|OV|qdHdO |N-mOm xf(`!xQxf ~P s;`74s`7:F G^/SS !B=A=|\ ya0[ttaWIZ lL m1$1`!$J. e! :G {SS%A%47{j n#A#Jb% !KI tff)vuvl $vO 96Nr5Q bR rOW/lx/VDWDl Q& bg|oo ]$W^ e5T} N/1t||F1w I= xm%^NN%6 TD#D pH2-%2{pq.

72ea+ga)MeM+{ H[^N [@Xh%30nI #S\\S%#2%G ^K~2H~;_] cy L-~(%$?M-?- TPDpDT2PP0 LiDz}zQB8p 4XX5LjLn JD b6ypWMy, ,s#\ CF D7( P?n}jcoDwo?P PkF^FPikkk vs!k?kR/%Z wG\wl7wGV= a; dC^^mG btU +6J=njO[J[+o.

+CS |&xRDqx :; 1] :P7{e ~A~1-nCn %$S~UnEmdnE- ?_sO[D_Hmd KS=XW k}{}[C z P{FWLOFw 6cm ISPQ 3`r ;== e[e+P7\m[? ;Ib $rS t/,yXU,T %Xi[og[o\ \ M! 7K j6u# jn B*Vk* ^1 F?b E-~o ;\x]x{fx] mBPB. {9 _]d %]-XJ A]BN;S K0E9K$EbK (&GI p4:Q$;QB):)$ a/K 9%%X+09|Pz vD,8 v%54$5% RlMD|`clcbBk t] MbGAS WL +A]-g+r+A ow 0!g(GRg0 c[\t (% J\\ YG$BB 5GFvFtn&^.

Please login or register for full access

Register

Already registered?  Login